Avidity Biosciences, Inc. RNA
Institutional shares held
116 Million
289K
calls
998K
puts
Total value of holdings
$3.59B
$8.93M
calls
$30.8M
puts
Market Cap
$1.61B
52,127,000
Shares Out.
Institutional ownership
222.57%
# of Institutions
244
We take great care to ensure that the data presented and summarized in this overview for Avidity Biosciences, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding RNA
View all-
Janus Henderson Group PLC London, X011.4MShares$353 Million0.19% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD11.3MShares$350 Million0.04% of portfolio
-
Wellington Management Group LLP Boston, MA9.68MShares$299 Million0.06% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.24MShares$286 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY8.75MShares$270 Million4.23% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$266 Million0.01% of portfolio
-
Avoro Capital Advisors LLC New York, NY7.63MShares$236 Million3.64% of portfolio
-
Ra Capital Management, L.P. Boston, MA6.3MShares$195 Million3.86% of portfolio
-
State Street Corp Boston, MA4.32MShares$134 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA2.76MShares$85.1 Million0.01% of portfolio
Latest Institutional Activity in RNA
Top Purchases
Top Sells
About RNA
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
Insider Transactions at RNA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 01
2025
|
Kathleen P. Gallagher Chief Program Officer |
SELL
Open market or private sale
|
Direct |
5,875
-10.41%
|
$188,000
$32.4 P/Share
|
|
May 01
2025
|
Kathleen P. Gallagher Chief Program Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,875
+9.43%
|
$94,000
$16.65 P/Share
|
|
Apr 01
2025
|
Kathleen P. Gallagher Chief Program Officer |
SELL
Open market or private sale
|
Direct |
5,875
-5.27%
|
$158,625
$27.83 P/Share
|
|
Apr 01
2025
|
Kathleen P. Gallagher Chief Program Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,875
+4.82%
|
$88,125
$15.68 P/Share
|
|
Mar 20
2025
|
W. Michael Flanagan Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
11,780
-12.81%
|
$365,180
$31.06 P/Share
|
|
Mar 20
2025
|
Sarah Boyce President and CEO |
SELL
Open market or private sale
|
Direct |
31,540
-9.35%
|
$977,740
$31.06 P/Share
|
|
Mar 20
2025
|
Steven George Hughes Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
9,578
-11.62%
|
$296,918
$31.06 P/Share
|
|
Mar 20
2025
|
Teresa Mc Carthy Chief Human Resources Officer |
SELL
Open market or private sale
|
Direct |
7,778
-7.41%
|
$241,118
$31.06 P/Share
|
|
Mar 20
2025
|
Michael F Mac Lean Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
7,935
-7.58%
|
$245,985
$31.06 P/Share
|
|
Mar 11
2025
|
W. Michael Flanagan Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
20,000
-17.86%
|
$600,000
$30.13 P/Share
|
|
Mar 11
2025
|
W. Michael Flanagan Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+15.15%
|
$280,000
$14.22 P/Share
|
|
Mar 03
2025
|
Kathleen P. Gallagher Chief Program Officer |
SELL
Open market or private sale
|
Direct |
5,875
-10.41%
|
$170,375
$29.41 P/Share
|
|
Mar 03
2025
|
Kathleen P. Gallagher Chief Program Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,875
+9.43%
|
$82,250
$14.7 P/Share
|
|
Feb 03
2025
|
Kathleen P. Gallagher Chief Program Officer |
SELL
Open market or private sale
|
Direct |
5,875
-10.41%
|
$188,000
$32.16 P/Share
|
|
Feb 03
2025
|
Kathleen P. Gallagher Chief Program Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,875
+9.43%
|
$94,000
$16.65 P/Share
|
|
Jan 22
2025
|
Kathleen P. Gallagher Chief Program Officer |
SELL
Open market or private sale
|
Direct |
5,629
-10.02%
|
$168,870
$30.16 P/Share
|
|
Jan 21
2025
|
Michael F Mac Lean Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,287
-1.53%
|
$92,036
$28.59 P/Share
|
|
Jan 21
2025
|
Arthur A Levin Director |
SELL
Open market or private sale
|
Direct |
1,872
-12.62%
|
$52,416
$28.6 P/Share
|
|
Jan 21
2025
|
Sarah Boyce President and CEO |
SELL
Open market or private sale
|
Direct |
10,397
-1.51%
|
$291,116
$28.59 P/Share
|
|
Jan 21
2025
|
W. Michael Flanagan Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
5,672
-2.94%
|
$158,816
$28.6 P/Share
|
Last 12 Months Summary
Buy / Acquisition
1.85M
Shares
From
17
Insiders
| Grant, award, or other acquisition | 873K shares |
|---|---|
| Exercise of conversion of derivative security | 952K shares |
| Bona fide gift | 22.5K shares |
Sell / Disposition
1.44M
Shares
From
9
Insiders
| Open market or private sale | 1.41M shares |
|---|---|
| Bona fide gift | 22.5K shares |